Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2017
Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials.
Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00002644 (International Breast Cancer Intervention Study), which is not on this map. Cited by 40 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
International Breast Cancer Intervention Study: A Multicentre Trial of Tamoxifen to Prevent Breast Cancer
Who cites it
40 citing papers in PubMed.
- Integrating breast cancer polygenic risk scores at scale in the WISDOM Study: a national randomized personalized screening trial.Genome medicine · 2025Trial
- Association of Polygenic-Based Breast Cancer Risk Prediction With Patient Management.JCO precision oncology · 2025Article
- Review
- Assessing the Value of Incorporating a Polygenic Risk Score with Nongenetic Factors for Predicting Breast Cancer Diagnosis in the UK Biobank.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- Development and testing of a polygenic risk score for breast cancer aggressiveness.NPJ precision oncology · 2023Article
- Integration of a Cross-Ancestry Polygenic Model With Clinical Risk Factors Improves Breast Cancer Risk Stratification.JCO precision oncology · 2023Article
- METTL1 gene polymorphisms synergistically confer hepatoblastoma susceptibility.Discover oncology · 2022Article
- Development and validation of polygenic risk scores for prediction of breast cancer and breast cancer subtypes in Chinese women.BMC cancer · 2022Article
- Association Between SNPs in the One-Carbon Metabolism Pathway and the Risk of Female Breast Cancer in a Chinese Population.Pharmacogenomics and personalized medicine · 2022Article
- Mammography screening and mortality by risk status in the California teachers study.BMC cancer · 2021Article
- Polygenic risk scores: the future of cancer risk prediction, screening, and precision prevention.Medical review (2021) · 2021Review
- Serum semaphorin 4C as a diagnostic biomarker in breast cancer: A multicenter retrospective study.Cancer communications (London, England) · 2021Article
- Evaluating Polygenic Risk Scores for Breast Cancer in Women of African Ancestry.Journal of the National Cancer Institute · 2021Article
- Elevated risk thresholds predict endocrine risk-reducing medication use in the Athena screening registry.NPJ breast cancer · 2021Article
- FromBreast care (Basel, Switzerland) · 2021Article
- Cases in Precision Medicine: The Role of Polygenic Risk Scores in Breast Cancer Risk Assessment.Annals of internal medicine · 2021Article
- Integrating Clinical and Polygenic Factors to Predict Breast Cancer Risk in Women Undergoing Genetic Testing.JCO precision oncology · 2021Article
- Genetic Factors, Adherence to Healthy Lifestyle Behavior, and Risk of Invasive Breast Cancer Among Women in the UK Biobank.Journal of the National Cancer Institute · 2020Article
- Key steps for effective breast cancer prevention.Nature reviews. Cancer · 2020Review
- Association of a Polygenic Risk Score With Breast Cancer Among Women Carriers of High- and Moderate-Risk Breast Cancer Genes.JAMA network open · 2020Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors.
Funding
Abstract
Purpose At least 94 common single nucleotide polymorphisms (SNPs) are associated with breast cancer. The extent to which an SNP panel can refine risk in women who receive preventive therapy has not been directly assessed previously. Materials and Methods A risk score on the basis of 88 SNPs (SNP88) was investigated in a nested case-control study of women enrolled in the International Breast Intervention Study (IBIS-I) or the Royal Marsden study. A total of 359 women who developed cancer were matched to 636 controls by age, trial, follow-up time, and treatment arm. Genotyping was done using the OncoArray. Conditional logistic regression and matched concordance indices (mC) were used to measure the performance of SNP88 alone and with other breast cancer risk factors assessed using the Tyrer-Cuzick (TC) model. Results SNP88 was predictive of breast cancer risk overall (interquartile range odds ratio [IQ-OR], 1.37; 95% CI, 1.14 to 1.66; mC, 0.55), but mainly for estrogen receptor-positive disease (IQ-OR, 1.44; 95% CI, 1.16 to 1.79; P for heterogeneity = .10) versus estrogen receptor-negative disease. However, the observed risk of SNP88 was only 46% (95% CI, 19% to 74%) of expected. No significant interaction was observed with treatment arm (placebo IQ-OR, 1.46; 95% CI, 1.13 to 1.87; tamoxifen IQ-OR, 1.25; 95% CI, 0.96 to 1.64; P for heterogeneity = .5). The predictive power was similar to the TC model (IQ-OR, 1.45; 95% CI, 1.21 to 1.73; mC, 0.55), but SNP88 was independent of TC (Spearman rank-order correlation, 0.012; P = .7), and when combined multiplicatively, a substantial improvement was seen (IQ-OR, 1.64; 95% CI, 1.36 to 1.97; mC, 0.60). Conclusion A polygenic risk score may be used to refine risk from the TC or similar models in women who are at an elevated risk of breast cancer and considering preventive therapy. Recalibration may be necessary for accurate risk assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.